News about Drug Discovery & Development

Lupin Gets Tentative Approval from FDA for Sitagliptin and Metformin Hydrochloride Tablets

Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Drug Discovery & Development | 02/12/2024 | By Aishwarya |  803

VectorBuilder Signs Deal with Sartorius to Advance Biopharmaceutical Innovation

The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.

Drug Discovery & Development | 29/11/2024 | By Aishwarya |  359

Glenmark Rolls Out Travoprost Ophthalmic Solution

Glenmark’s Travoprost Ophthalmic Solution USP, 0.004 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004 percent of Sandoz, Inc.

Drug Discovery & Development | 27/11/2024 | By Aishwarya |  441

Boehringer Ingelheim Unveils VETMEDIN Solution

VETMEDIN Solution, now available in the US, provides the same dual mode of action as VETMEDIN® Chewable Tablets.

Drug Discovery & Development | 25/11/2024 | By Aishwarya |  497

Dr. Jitendra Singh Announces Soft Launch of Antibiotic Nafithromycin

The antibiotic ‘Nafithromycin’ has been developed with the support of Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology and has been brought to market under the trade name ‘Miqnaf’ by pharma company ‘Wolkardt’.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  994

Lupin Introduces Bumetanide Injection in US

Bumetanide Injection USP, is a generic equivalent of Bumex Injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  463

Alloy Therapeutics Signs License Deal with Takeda to Develop Cell Therapy Platform

Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications.

Drug Discovery & Development | 21/11/2024 | By Aishwarya |  397

Syndax Gets FDA Approval of Revuforj for Relapsed or Refractory Acute Leukemia

The safety evaluation of Revuforj was based on an FDA analysis of 135 patients with R/R acute leukemia with a KMT2A translocation who were treated with Revuforj.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  459

Endo and Paladin Pharma to Commercialize Wynzora Cream in Canada

Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  556

Reverb, Royalmount Laboratories to Develop Advanced Bispecific Antibodies

Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody-tissue interaction to amplify endogenous cytokines and redirect them to tissues of interest.

Drug Discovery & Development | 14/11/2024 | By Aishwarya |  437